Search results
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $33.53
ETF DAILY NEWS· 19 hours agoPTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the thirteen ratings firms that are ...
PTC Therapeutics Q1 2024 Earnings: A Detailed Financial Review
Guru Focus· 1 day agoThis quarter, the company reported significant achievements, including robust revenue performance and the advancement of key regulatory submissions. PTC Therapeutics ...
PTC Therapeutics (PTCT) to Release Earnings on Thursday
ETF DAILY NEWS· 4 days agoPTC Therapeutics (NASDAQ:PTCT – Get Free Report) is set to release its earnings data after the market closes on Thursday, April 25th. Analysts expect < ...
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
WKRN Nashville· 1 day agoPTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024. "We are off ...
Q1 2024 PTC Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 10 hours agoParticipants Jane Hanlon; Associate Director, Investor Relations; PTC Therapeutics Inc Matthew Klein; Independent Director; PTC
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
Zacks via Yahoo Finance· 22 hours agoAlthough the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed...
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 787 Shares of Stock
ETF DAILY NEWS· 7 days agoPTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) CEO Eric Pauwels sold 787 shares of PTC Therapeutics stock ...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PAHomePage.com· 3 days agoPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved...
PTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...
GuruFocus.com via Yahoo Finance· 14 hours agoA: Matthew Klein, Independent Director at PTC Therapeutics, emphasized the strong data set from APHENITY and the long-term extension, which positions the ...
A company insider recently sold 3,361 shares of PTC Therapeutics Inc [PTCT]. Should You Sale? – Knox...
Knox Daily· 2 days agoInvestors can speculate about the future of a stock by watching how its insiders buy and sell stocks. PTC Therapeutics Inc shares valued at $83,669 were ...